1-己基-5-氧代吡咯烷-3-羧酸 | 116167-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-己基-5-氧代吡咯烷-3-羧酸
• 英文名称: 1-Hexyl-4-carboxy-2-pyrrolidone
• 英文别名: 1-Hexyl-5-oxopyrrolidine-3-carboxylic acid
• CAS: 116167-27-2
• 化学式: C₁₁H₁₉NO₃
• mdl: MFCD01688138
• 分子量: 213.277
• InChiKey: VHKDTUOUWLJSJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (2R,4R)-2-[(1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl]-4-benzyloxypyrrolidine-1-carboxylic acid tert-butyl ester 、 1-己基-5-氧代吡咯烷-3-羧酸 在 N-羟基-7-氮杂苯并三氮唑 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 生成 、
  参考文献：
  名称：

  Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor

  摘要：

  Based on a lead compound identified from the patent literature, we developed patentably novel BACE-1 inhibitors by introducing a cyclic amine scaffold as embodied by la and 1b. Extensive SAR studies assessed a variety of isophthalamide replacements including substituted pyrrolidinones and ultimately led to the identification of 11. Due to its favorable overall profile, 11 has been extensively profiled in various in vivo settings. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.053

文献信息

• COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME
  申请人：Midatech Limited

  公开号：US20150099698A1

  公开（公告）日：2015-04-09

  Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.

  纳米颗粒具有核心和与核心共价连接的配体环，其中不同种类的肽与纳米颗粒结合，并纳入各种剂型中。
• [EN] CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT<br/>[FR] INHIBITEURS D'AMINES CYCLIQUES BACE-1 RENFERMANT UN SUBSTITUANT HETEROCYCLIQUE
  申请人：SCHERING CORP

  公开号：WO2005014540A1

  公开（公告）日：2005-02-17

  Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25) or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

  揭示了具有以下结构的新化合物（I）或其药学上可接受的盐或溶剂，其中R1为结构（I），X为-0-，-C(R14)2-或-N(R)-；Z为-C(R14)2-或-N(R)-；t为0、1、2或3；每个R和R2独立地为H、烷基、环烷基、环烷基烷基、芳基、杂环芳基、杂环烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、烯基或炔基；每个R14为H、烷基、烯基、炔基、卤素、-CN、卤代烷基、环烷基、环烷基烷基、芳基、杂环芳基、芳基烷基、杂环芳基烷基、杂环烷基烷基、-OR35、-N(R24)(R25)或-SR35；R41为烷基、环烷基、-S02(烷基)、-C(O)-烷基、-C(O)-环烷基或-烷基-NH-C(O)CH3；其余变量如规范中所定义。还揭示了包括化合物的药物组合物（I）的制剂以及使用化合物（I）治疗认知或神经退行性疾病的方法。还揭示了包括化合物（I）的药物组合物和治疗方法，其与治疗认知或神经退行性疾病有用的其他药剂结合使用。
• TRPV1 agonist compounds and methods for making and using the same
  申请人：Jamieson Curtis Gene

  公开号：US20060240097A1

  公开（公告）日：2006-10-26

  Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.

  这里描述了TRPV1激动剂化合物及其合成和使用方法。除了具体识别的化合物外，还描述了辣椒素前药、双子星二聚体和相互前药。TRPV1激动剂化合物的配方可以是液体、片剂、胶囊、凝胶、乳霜、乳状液、贴片等形式。还提供了使用所述化合物、组合物或前药治疗医疗状况的方法。
• COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES
  申请人：Richard Herve

  公开号：US20140294743A1

  公开（公告）日：2014-10-02

  The present invention relates to a cosmetic and/or dermatological composition comprising in a physiologically acceptable medium at least one merocyanine derivative of formula (1) or (2) and/or its E,E-, E,Z- or Z,Z-geometrical isomer forms: comprising specific polar groups consisting of hydroxyl- and ether-functionalities. Another object of the present invention relates to a cosmetic process for controlling and/or improving the darkening of the skin under exposure to UV radiation and the homogeneity of the colour of the complexion which comprises the application onto the skin of a cosmetic composition as above defined. Another object of the present invention relates to a cosmetic process for protecting the keratinic materials and particularly the skin against photo-ageing which comprises the application onto the keratinic material of a cosmetic composition as above defined.

  本发明涉及一种化妆品和/或皮肤科学组合物，其在生理上可接受的介质中包含至少一种公式（1）或（2）的merocyanine衍生物及/或其E，E-，E，Z-或Z，Z-几何异构体形式：包括由羟基和醚功能团组成的特定极性基团。本发明的另一个目的涉及一种化妆过程，用于控制和/或改善皮肤在紫外线照射下的变黑和肤色均匀性，包括在皮肤上涂抹上述定义的化妆品组合物。本发明的另一个目的涉及一种化妆过程，用于保护角质素材料，特别是皮肤免受光老化的影响，包括在角质素材料上涂抹上述定义的化妆品组合物。
• [EN] USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES<br/>[FR] UTILISATION DE PROMÉDICAMENTS DE CANNABIDIOL POUR ADMINISTRATION TOPIQUE ET TRANSDERMIQUE AVEC DES MICRO-AIGUILLES
  申请人：ALLTRANZ INC

  公开号：WO2011026144A1

  公开（公告）日：2011-03-03

  Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

  本文描述了微针药物递送系统，包括含有药物活性成分（例如大麻二酚和大麻二酚前药）的药物组合物和适用于将活性成分局部或全身性递送至哺乳动物的微针阵列。本文还描述了使用微针经皮或局部药物递送系统治疗疾病，包括胰腺炎和胰腺癌的方法，其中药物组合物包括大麻二酚和大麻二酚前药，并且使用微针阵列。